Case Studies &Client Outcomes

Challenge

A mid-sized biopharma with 25+ oncology pipeline assets lacked a systematic framework for portfolio prioritization. Investment decisions were made reactively based on individual champion advocacy rather than data-driven analysis. The company was burning $180M annually across the portfolio with no clear go/no-go governance, leading to resource misallocation, delayed termination of high-risk programs, and an increasingly unsustainable R&D burn rate relative to its revenue base.

Challenge

A specialty pharmaceutical company with established products in dermatology and cardiology planned to diversify into rare diseases but had no framework for selecting which indications to pursue. Their leadership team had identified 15+ rare diseases of interest based on anecdotal market reports, but lacked systematic analysis of patient populations, competitive intensity, regulatory pathways, pricing potential, and development feasibility. Without a structured approach, they risked investing $50-100M in development programs targeting indications with limited commercial potential or insurmountable competition.

Challenge

A gene therapy company preparing for their first commercial launch faced unprecedented pricing challenges. Their therapy was a one-time treatment for a rare pediatric disease with an addressable population of 3,000 patients in the US. The company wanted to price at $2.1M per patient based on cost-effectiveness analysis, but had no experience with payer negotiations, no outcomes-based agreement templates, and no understanding of payer willingness-to-pay for one-time therapies. Three recent gene therapy launches had struggled with payer access, and 2 had been forced to accept significant price reductions.

Challenge

A top-20 pharma company with an established cardiovascular portfolio generating $1.8B in revenue faced stagnating growth in developed markets due to generic erosion and payer pressure. They needed an emerging markets expansion strategy across 8 countries in Asia-Pacific and Latin America, but lacked local market intelligence, regulatory pathway knowledge, and partnership frameworks. Previous attempts at emerging market entry had failed due to poor partner selection and inadequate pricing strategies.

Challenge

A mid-sized biopharma with 25+ oncology pipeline assets lacked a systematic framework for portfolio prioritization. Investment decisions were made reactively, leading to resource misallocation and delayed termination of high-risk programs.

Challenge

A specialty pharma company planned to enter the rare disease space but lacked clarity on which indications offered the best opportunity. They needed disease burden analysis, treatment landscape mapping, and competitive intelligence across 15+ rare indications.

Challenge

An emerging pharma company launching their first commercial oncology product needed a comprehensive market access and pricing strategy across 15 markets. They had no prior pricing experience and faced complex payer landscapes.

Challenge

A mid-sized pharma company launching a next-generation diabetes therapy needed a comprehensive commercial excellence program. Their sales force lacked launch experience and competitive positioning was unclear against 12 established products.

Challenge

A top-20 pharma company with an established cardiovascular portfolio needed an emerging markets expansion strategy across 8 countries in Asia-Pacific and Latin America. They lacked local market intelligence and partnership frameworks.

Challenge

A mid-cap pharma company with $2B revenue faced a growth plateau with 3 products approaching loss-of-exclusivity. They needed a corporate growth strategy covering portfolio diversification, BD&A targets, and geographic expansion.

Challenge

A pharma company needed to evaluate 10 biologics for biosimilar development potential. They lacked comprehensive market analysis covering patent expiry, market size evolution, competitive biosimilar pipeline, and pricing erosion projections.

Challenge

A biopharma company with a Phase II cardiovascular asset targeting heart failure needed to benchmark their proposed Phase III trial design against 40+ competing programs. Their current design had a projected enrollment timeline of 42 months, a composite primary endpoint that had not been used in recent approvals, and no clear competitive positioning relative to 4 drugs that had launched in the same indication in the past 3 years. The CMO was concerned that the trial design would result in a 6-12 month delay to market entry.

Challenge

A vaccine manufacturer needed to modernize their clinical development process with decentralized trial capabilities. Their traditional site-based model was resulting in slow enrollment (averaging 14 months for Phase III trials), limited patient diversity (72% white participants in US trials), and outdated paper-based data collection with 8-12 week data lock delays. A competing vaccine manufacturer had recently launched a decentralized trial that enrolled in 6 months with 45% diversity — creating competitive pressure to modernize.

Challenge

A biopharma company with a Phase II cardiovascular asset needed to benchmark their trial design against 40+ competing programs. They lacked visibility into endpoint selection, enrollment timelines, and competitive positioning.

Challenge

A vaccine manufacturer needed to modernize their clinical development process with decentralized trial capabilities. They faced slow enrollment, limited patient diversity, and outdated data collection methods across 20+ trial sites.

Challenge

A pharma company with 2 approved oncology products needed a comprehensive therapy area analysis to guide expansion into 5 additional oncology indications. They lacked disease-level intelligence across treatment landscapes, emerging therapies, and unmet needs.

Challenge

A biotech company with a first-in-class neurology therapeutic for a rare epilepsy syndrome needed a regulatory strategy across FDA, EMA, and PMDA. They had completed Phase II with promising efficacy data but had no regulatory strategy, no clarity on accelerated approval pathways, and no understanding of orphan drug designation potential. Their standard development plan projected a 2028 approval — 5 years away — which was uncompetitive given that 2 competitors had entered Phase III.

Challenge

A biotech company with a first-in-class neurology therapeutic needed a regulatory strategy across FDA, EMA, and PMDA. They lacked clarity on accelerated approval pathways, orphan drug designation potential, and comparative regulatory requirements.

Challenge

A gene therapy company preparing for their first commercial launch needed a comprehensive pricing and HEOR strategy. They faced unprecedented pricing challenges with a one-time therapy and uncertain payer willingness-to-pay.

Challenge

A global pharma company with operations in 40+ countries needed an enterprise risk management and compliance framework. They faced fragmented risk reporting, inconsistent compliance standards, and growing regulatory scrutiny across markets.

Challenge

A top-10 pharma company preparing for a major immunology launch had an outdated KOL list compiled 3 years ago through manual recommendations. The list contained 75 names with limited influence mapping, no tiering rationale, and no coverage of digital opinion leaders (DOLs). The medical affairs team needed to identify, profile, and engage 200+ KOLs across 12 markets with a data-driven, defensible approach. The existing list had known gaps in emerging markets and underrepresented the growing community of digital-first opinion leaders.

Challenge

A top-10 pharma company preparing for an immunology launch had an outdated KOL list with limited influence mapping. They needed to identify, profile, and engage 200+ KOLs across 12 markets with a data-driven approach.

Challenge

A biotech company preparing for a rare disease product launch had an underdeveloped medical affairs function. They needed a comprehensive medical strategy, publication plan, and MSL engagement framework to build scientific credibility.

Challenge

A top-10 pharma company with a chronic disease portfolio needed to embed patient-centricity across their development and commercial processes. They lacked patient journey maps, engagement metrics, and advocacy relationships.

Challenge

A dermatology-focused biotech launching a psoriasis therapy needed primary research with 150+ physicians across 8 markets to understand prescribing behavior, treatment gaps, and competitive positioning.

Challenge

A top-15 pharma company was evaluating a $800M acquisition of a late-stage biotech with 3 assets: one Phase III oncology drug, one Phase II autoimmune drug, and one Phase I neurology drug. The BD team had 4 weeks to deliver a commercial due diligence report to the investment committee. They needed risk-adjusted peak sales forecasts, competitive landscape analysis, pricing and reimbursement risk assessment, and a clear go/no-go recommendation with valuation support.

Challenge

A generic pharmaceutical company developing a biosimilar portfolio needed comprehensive patent landscape analysis and freedom-to-operate (FTO) assessment for 5 reference biologic products. They faced complex patent thicket challenges — each reference product was protected by 40-80 patents covering composition, manufacturing methods, formulations, and indications. Without a clear FTO analysis, they risked investing $200M+ in development only to face patent infringement litigation at launch.

Challenge

A top-15 pharma company was evaluating a $800M acquisition of a late-stage biotech with 3 assets. They needed commercial due diligence covering market sizing, competitive landscape, peak sales forecasting, and risk assessment.

Challenge

A generic pharma company developing a biosimilar portfolio needed comprehensive patent landscape analysis and freedom-to-operate assessment for 5 reference products. They faced complex patent thicket challenges and unclear launch timing.

Challenge

A cell therapy company transitioning to commercial manufacturing needed CDMO selection, supply chain design, and quality systems consulting. They faced complex logistics requirements and limited manufacturing experience.